At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 169 enrolled
Drug / intervention
Bevacizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Ipilimumab for Stage IIIC Cutaneous Melanoma AJCC v7 and 2 related conditions. Completed, enrolled 169 participants across 482 sites.
Detailed Summary
This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartJan 2014
Primary CompletionOct 2021
Study CompletionJan 2025
TodayJul 2026
First PostedSep 25, 2013
Enrollment StartJan 24, 2014
Primary CompletionOct 6, 2021
Study CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 12.8 years ago
Interventions
Bevacizumabbiological
Given IV
Ipilimumabbiological
Given IV